Janus Henderson Group’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Janus Henderson Group’s Portfolio BIOTU Stock Details BIOTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-41,715	Closed	-$413K	–	2728
2022 Q1	$413K	Hold	41,715	–	–	﹤0.01%	2024
2021 Q4	$424K	Hold	41,715	–	–	﹤0.01%	1996
2021 Q3	$419K	Hold	41,715	–	–	﹤0.01%	1704
2021 Q2	$420K	Buy	41,715 +16,715	+67%	+$167K	﹤0.01%	1459
2021 Q1	$248K	Buy	+25,000	New	+$257K	﹤0.01%	1449

Other funds holding BIOTU

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Janus Henderson Group's BIOTU Position: Q2 2022 in Review

Janus Henderson Group sold out of Biotech Acquisition Company Unit (BIOTU) in Q2 2022, closing a stake of 41,715 shares — an estimated $413K sold.

Janus Henderson Group first reported a position in BIOTU in Q1 2021 and held it in 5 quarters. The position peaked at $424K in Q4 2021. 5 funds tracked by Wall St. Rank hold BIOTU as of Q2 2022.

Janus Henderson Group reported no remaining Biotech Acquisition Company Unit position as of Q2 2022 after selling out during the quarter.
Janus Henderson Group sold 41,715 Biotech Acquisition Company Unit shares in Q2 2022, an estimated $413K.
Janus Henderson Group first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 5 quarters.
Janus Henderson Group's Biotech Acquisition Company Unit position peaked at $424K in Q4 2021.
5 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q2 2022.

Based on Janus Henderson Group's 13F filing for Q2 2022, filed 15 Aug 2022.